Does Combination Therapy With a Glucagon-Like Peptide-1 Receptor Agonist and a Sodium-Glucose Cotransporter 2 Inhibitor Enhance Cardiovascular and Renal Protection in People With Type 2 Diabetes Mellitus? - Cureus
Sentiment Mix
Geography
Expert Signals
Politics - Google News CA Headlines
source • 1 mention
AI-Generated Claims
Generated from linked receipts; click sources for full context.
Does Combination Therapy With a Glucagon-Like Peptide-1 Receptor Agonist and a Sodium-Glucose Cotransporter 2 Inhibitor Enhance Cardiovascular and Renal Protection in People With Type 2 Diabetes Mellitus?
Supported by 1 story
CureusCardiovascular and renal outcomes of combined SGLT2 inhibitors and GLP-1 receptor agonists versus monotherapy in patients with type 2 diabetes mellitus: a network meta-analysis CMAJ
Supported by 1 story
Related Events
Johnson & Johnson CFO Says Guidance Hike Is Just the Start - Barron's
Uncategorized • 7/16/2026
New Brunswick vows improvements to virtual care after criticism of new provider
Uncategorized • 7/16/2026
Trump admin replaces slavery memorial at President's House in Philadelphia
Uncategorized • 7/16/2026
Israel Expands Tourism Infrastructure With New Hotels and Major Investments - TravelAge West
Hardware • 7/16/2026
Should Canadians avoid American produce amid cyclosporiasis spread?
Uncategorized • 7/16/2026